6 Best Peptides for Nerve Pain

What to Know Before Choosing a Peptide for Nerve Pain

Nerve pain is one of the harder problems in medicine. The standard toolkit, gabapentin, pregabalin, opioids, and NSAIDs, works mostly by muffling pain signals rather than addressing the underlying nerve damage. Peptides enter the conversation from a different angle. Some aim to physically rebuild damaged nerve fibers. Some target the inflammation that keeps pain active after the original injury heals. Some do both at once. The interest is real, and so is the caution that belongs alongside it.

A peptide earned a slot on this list because people are using it or actively discussing using it for nerve pain. That is the whole test. FDA approval, telemedicine prescription status, and the depth of the published literature are not the filters here. This list includes compounds with human clinical evidence alongside compounds whose evidence base is almost entirely experiential, and both kinds belong. The evidence for each compound is described honestly inside its entry, and the difference between a compound studied in controlled trials and one supported only by community reports is stated plainly rather than papered over.

The numbers in front of each entry are an ordering, not a ranking. They reflect how prominently each compound appears in the research and in real-world use for nerve pain. They are not a verdict that one compound is better for you than another. Individual goals, health histories, and circumstances shape that decision in ways a general article cannot. That is what the app is for.

One important framing note before the list: no peptide discussed here is FDA-approved specifically for nerve pain or neuropathy. The only FDA-approved peptide for severe chronic pain is ziconotide, a neurotoxin delivered via an implanted spinal pump in clinical settings, which functions as a pain blocker rather than a nerve repair agent. Every compound below sits outside that approval pathway, accessible through research chemical suppliers, compounding pharmacies, or peptide therapy clinics depending on the compound.

1. BPC-157: For Axonal Regeneration and Central Pain Modulation

BPC-157, short for Body Protection Compound-157, is a synthetic peptide of 15 amino acids derived from a protective protein found in gastric juice. It is by a significant margin the most widely used and discussed peptide for nerve pain across clinical peptide therapy practices and online communities. If someone is asking about peptides for nerve pain anywhere, BPC-157 is almost certainly part of the conversation.

The reason for that prominence is its proposed mechanism. BPC-157 appears to promote angiogenesis, the growth of new blood vessels, which increases the supply of oxygen and nutrients to damaged nerve tissue. More directly relevant to nerve repair, animal research suggests it supports axonal regeneration, meaning the physical regrowth of damaged nerve fibers themselves, rather than simply blocking pain signals. It also interacts with central pain signaling pathways, reducing both inflammatory and non-inflammatory pain through mechanisms that researchers have not yet fully characterized at the receptor level.

For a compound this widely used, the published human evidence is strikingly thin. No peer-reviewed randomized controlled trial has examined BPC-157 specifically for nerve pain or neuropathy in humans as of 2026. The available human data consists of one unpublished oral study and one retrospective injection study focused on joint pain rather than neuropathy. The backbone of the published evidence is animal model research, which is consistent and encouraging but has not been validated in a controlled human population.

Community reports fill some of that gap. Users across peptide forums describe meaningful recovery from specific neuropathic conditions. One commonly cited account involves ulnar nerve damage with reduced numbness and restored hand function within three weeks. Reports from users with sciatica describe noticeable changes within days, including restored warmth and blood flow to the affected area, with outcomes described as comparable to steroid injections. These are self-reported accounts with all the limitations that implies: no controls, no objective measurement, and significant variability from person to person.

The safety picture deserves honest treatment. Theoretical concerns include pathologic angiogenesis, meaning abnormal or excessive blood vessel growth, and caution has been raised specifically for anyone with active or recent cancer given that angiogenesis also supports tumor growth. BPC-157 is prohibited by the World Anti-Doping Agency for competitive sports. Researchers have consistently called for caution given the absence of human RCTs. Those cautions do not make BPC-157 unusual in this field. It remains the most community-studied compound on this list by a wide margin, and that community has been running protocols and sharing outcomes for years.

2. TB-500: For Remyelination and Anti-Inflammatory Support

TB-500 is a synthetic version of Thymosin Beta-4, a peptide found naturally in essentially every cell in the human body. It appears in nerve pain discussions almost exclusively alongside BPC-157 rather than as a standalone choice, and the pairing has become common enough in clinical peptide therapy settings that the two are often thought of as a unit.

The mechanistic rationale for pairing them is clear. Where BPC-157 is primarily discussed for axonal regeneration and angiogenesis, TB-500 is used for complementary aspects of nerve repair. Animal research suggests it supports remyelination, meaning the restoration of the myelin sheath that insulates nerve fibers and enables efficient signal transmission. A nerve with a damaged myelin sheath transmits signals poorly, which presents as pain, numbness, or both. TB-500 also appears to suppress the inflammatory cytokines that perpetuate nerve damage after the original injury, and to reduce fibrosis, the buildup of scar tissue around injured nerves that can maintain compression and pain long after the initial event.

The human evidence for TB-500 in nerve conditions is limited. Almost all published research comes from animal models, and no quality human randomized controlled trials examining TB-500 for neuropathic conditions have been published as of 2026. Community reports describe it primarily as an enhancer of BPC-157's effects rather than a compound with a distinctive standalone profile for nerve pain. Users running both compounds together report better outcomes than they recall from either alone, but that kind of stacked anecdotal comparison is not controlled evidence.

TB-500 carries the same WADA prohibition as BPC-157 and is classified as a research compound in the United States. The safety profile at amounts used in community protocols has not been examined in controlled human trials, and the same honest uncertainty that applies to BPC-157 applies here.

3. ARA 290: For Small Fiber Neuropathy and Immune-Driven Nerve Damage

ARA 290, also known as cibinetide, is a synthetic peptide derived from the non-hematopoietic portion of erythropoietin, the hormone best known for stimulating red blood cell production. Its key feature is that it specifically activates what researchers call the Innate Repair Receptor, a tissue protection and repair pathway, without triggering erythropoietin's blood-cell-stimulating effects. That selective activation is what makes it relevant to nerve pain: the repair signaling can be switched on without the concerns that come with erythropoietin itself.

The mechanism is most clearly relevant to nerve damage that is immune-driven or inflammatory in origin. ARA 290 inhibits pro-inflammatory signaling and down-regulates the overactive immune responses that continue damaging nerve tissue after an initial insult. In animal models using the spared nerve injury method, it significantly alleviates both mechanical allodynia, pain triggered by non-painful touch, and cold allodynia, pain triggered by non-painful cold. Published preclinical research also shows activity in diabetic neuropathy models, where chronic inflammation and small fiber damage are central to the condition's progression.

Community reports for ARA 290 are notably specific. People tracking outcomes for small fiber neuropathy, a condition affecting the tiniest nerve fibers that is notoriously resistant to conventional treatment, report symptom improvements of roughly 50 percent within days to weeks at sufficient amounts. A consistent observation in these reports is strong dosage dependence: users describe no perceivable benefit at lower amounts and meaningful relief only at higher ones. The effects are also described as temporary, with pain returning within one to two weeks of stopping use, which means ongoing cycles are needed to maintain benefit. That requirement, combined with ARA 290's relatively high cost, limits long-term accessibility for many users.

Compared to BPC-157, ARA 290 has a more targeted published evidence base for a specific subtype of nerve pain, and the preclinical literature maps more directly onto small fiber and immune-mediated presentations. For someone dealing specifically with small fiber neuropathy, it is the compound in the current conversation drawing the most consistent community reports for that presentation.

4. Cerebrolysin: For Neurotrophic Support in Nerve Repair

Cerebrolysin is not a single molecule. It is a mixture of low-molecular-weight neuropeptides and amino acids derived from purified porcine brain proteins. The mixture contains compounds that mimic the action of endogenous neurotrophic factors, the signaling proteins the nervous system uses to maintain neuronal survival, support axonal growth, and drive repair after damage. It has been used clinically in parts of Europe and Asia for decades, primarily for stroke recovery, traumatic brain injury, and cognitive decline, where neurotrophic and neuroprotective effects are the primary rationale.

Its relevance to nerve pain runs through that same neurotrophic mechanism. The nervous system's capacity to repair damaged nerve fibers depends in part on adequate neurotrophic signaling, particularly factors similar to nerve growth factor and brain-derived neurotrophic factor. Cerebrolysin's peptide mixture appears to support neuronal survival under stress and the conditions needed for axonal regrowth. It also provides protection against oxidative damage to neurons, which matters in contexts like diabetic neuropathy where chronic oxidative stress is part of the damage mechanism.

The clinical evidence for Cerebrolysin in neuropathic pain specifically is limited. Its strongest published evidence base is in stroke recovery and cognitive conditions, where it has been examined in multiple controlled trials in European populations and holds approved therapeutic status in several countries. For peripheral neuropathy and nerve pain as a primary indication, controlled human trial data is sparse. Use within the nerve pain community tends to be off-label, with practitioners drawing on the broader neurotrophic rationale rather than specific neuropathy trial data.

Cerebrolysin requires injection by intramuscular or intravenous route and is given in courses over multiple consecutive days. That administration profile places it squarely in clinical settings rather than self-managed protocol territory. In the United States it is classified as a research compound and is not FDA-approved. It remains one of the more seriously evidenced compounds in the neurological peptide space globally, even if that evidence does not map cleanly onto peripheral neuropathy as a specific indication.

5. Semax: For Neurotrophic Recovery After Nerve Injury

Semax is a synthetic heptapeptide, seven amino acids, derived from a fragment of ACTH, the adrenocorticotropic hormone involved in the body's stress response. It was developed in Russia and has been used clinically there for neurological conditions including ischemic stroke, optic nerve injury, and traumatic brain events. Outside Russia it is classified as a research compound and is not approved for any indication in the United States or the European Union.

Its mechanism in the context of nerve injury centers on BDNF, brain-derived neurotrophic factor, one of the most important growth factors in the nervous system's repair process. Semax upregulates BDNF expression and supports synaptogenesis, the formation of new synaptic connections between neurons. It also provides direct neuroprotection through neurotrophic signaling. Russian clinical use has extended it to peripheral nerve recovery, including conditions where restoration of nerve function is the goal.

The evidence from Western published literature for Semax in neuropathic pain is thin. No randomized controlled trials in English-language peer-reviewed journals have examined it specifically for nerve pain as of 2026. What exists is the Russian clinical tradition, a coherent mechanistic rationale based on BDNF's role in nerve repair, and community use among people running neurological recovery protocols who include Semax as a neurotrophic component. It tends to appear in nerve pain discussions as a supporting compound rather than a primary choice, particularly alongside compounds like BPC-157 that target the physical tissue repair side.

Semax is typically administered intranasally, which distinguishes it from the injectable compounds above and lowers the barrier for some users. Community experience describes it as well-tolerated, and the Russian clinical safety record across decades of neurological use provides some real-world signal even though it does not translate into controlled US-population data.

6. Cortagen: For Nerve Tissue Homeostasis at the Cellular Level

Cortagen is a tetrapeptide bioregulator, four amino acids, developed as part of the Russian peptide bioregulator research program that began in the 1970s. It belongs to a class of compounds called cytomaxes, short peptide regulators designed to target specific tissues and restore cellular function at the gene-expression level. Cortagen's target tissue is neural, making it the member of the cytomax class most directly relevant to nervous system conditions.

The proposed mechanism follows the broader cytomax framework. Short peptide bioregulators in this class are understood to enter cell nuclei and interact with DNA-binding proteins, influencing gene expression in a tissue-specific way. For Cortagen, the hypothesis is that this regulation supports neuronal tissue homeostasis, meaning the maintenance of normal cellular function in nerve tissue that has become dysregulated by damage, aging, or chronic inflammation. This is a regulatory and restorative mechanism rather than a signal-blocking or direct regeneration mechanism.

The human evidence base for Cortagen in nerve pain is limited. It does not have the community reporting volume of BPC-157 or ARA 290, and no published human randomized controlled trials for neuropathic pain exist in the available literature as of 2026. What exists comes from the broader Russian bioregulator research tradition, which has examined this class of compounds over decades with an emphasis on tissue-specific restoration, and from community protocols shared among people using bioregulator stacks for neurological conditions.

Cortagen appears most often in discussions among people exploring the Russian peptide bioregulator family as part of a broader nervous system support approach. It is available as a research compound and is sold in some markets as a dietary supplement, though regulatory status varies by country. Its use in the nerve pain community is real but limited in volume, and the evidence here is experiential rather than clinical. Anyone considering it should approach it with the understanding that the experience base is far smaller than the compounds higher on this list.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for nerve pain?

No peptide on this list is FDA-approved specifically for nerve pain or neuropathy. The only FDA-approved peptide for severe chronic pain is ziconotide, a neurotoxin delivered via an implanted intrathecal pump in clinical settings, which works by blocking pain signals rather than repairing nerve tissue. Every compound covered in this guide is accessed through research chemical suppliers, compounding pharmacies, or peptide therapy clinics, and none has cleared the full FDA approval process for a neuropathic pain indication.

How do peptide approaches to nerve pain differ from gabapentin or pregabalin?

Gabapentin and pregabalin work by modulating calcium channels in the nervous system to reduce the transmission of pain signals. They are symptom management tools, not repair agents. Peptides like BPC-157 and ARA 290 are used with a different goal: addressing the underlying nerve damage by promoting axonal regrowth, reducing neuroinflammation, or restoring the myelin sheath. Whether they succeed at that goal in humans is not yet established by controlled clinical trials, but the mechanistic difference from conventional treatments is the core reason they attract interest among people whose nerve pain has not resolved with standard approaches.

Do the effects of these peptides last after stopping use?

It depends on the compound and the condition. Community reports for ARA 290 consistently describe effects that fade within one to two weeks after stopping, suggesting ongoing use is needed to maintain benefit. BPC-157 users report more durable changes in some cases, particularly for structural nerve damage where the proposed mechanism involves actual tissue repair, but outcomes vary considerably from person to person. No compound on this list has been studied in controlled conditions long enough to make a reliable statement about durability of effect after discontinuation.

Is there any peptide for nerve repair with strong human clinical evidence?

The strongest human clinical evidence for a peptide that restores nerve function, rather than blocking pain, currently comes from NVG-291, a compound in active Phase II clinical development for spinal cord injury. Trial participants showed measurable improvements in hand function and nerve conduction at 12 weeks. NVG-291 is not available for general use. Among the compounds people can currently access, none has a completed Phase II or Phase III human randomized controlled trial specifically for neuropathic pain. Cerebrolysin has the most substantial human clinical history of any compound on this list, though its strongest data is in stroke recovery and cognitive conditions rather than peripheral neuropathy.

What types of nerve pain do people most commonly use peptides for?

The conditions that come up most often in community discussions are diabetic peripheral neuropathy, sciatica, chemotherapy-induced peripheral neuropathy, small fiber neuropathy, and nerve damage from injury such as ulnar nerve damage or post-surgical nerve trauma. ARA 290 draws particularly consistent community attention for small fiber neuropathy. BPC-157 and TB-500 are used across the widest range of presentations. People with spinal cord injury make up the primary community currently tracking NVG-291's clinical development.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for nerve pain in one place.